The withdrawal of mibefradil (Posicor)
Griffin, J.P.
Adverse Drug Reactions and Toxicological Reviews 17(2-3): 59-60
1998
ISSN/ISBN: 0964-198X PMID: 9838964 Document Number: 491931
Document emailed within 1 workday
Related Documents
Welker, H.A.; Banken, L. 1998: Mibefradil pharmacokinetic and pharmacodynamic population analysis International Journal of Clinical Pharmacology Research 18(2): 63-71Komiyama, T. 1997: Clinical features of alcoholics after alcohol withdrawal--withdrawal syndrome, protracted withdrawal syndrome and prolonged disturbance of alcohol dependence Nihon Rinsho. Japanese Journal of Clinical Medicine 55 Suppl: 393-405
Vacher, E.; Richer, C.; Fornes, P.; Clozel, J.P.; Giudicelli 1996: Mibefradil, a selective calcium T-channel blocker, in stroke-prone spontaneously hypertensive rats Journal of Cardiovascular Pharmacology 27(5): 686-694
Emanuel, K.; Mackiewicz, U.; Pytkowski, B.; Lewartowski, B. 1998: Effects of mibefradil, a blocker of T-type Ca2+ channels, in single myocytes and intact muscle of guinea-pig heart Journal of Physiology and Pharmacology: An Official Journal of the Polish Physiological Society 49(4): 577-590
Levy, R.; le Maignan, C.; N'Daw, D.; Andrieu, J.M. 1997: An equivalent of anti-androgen withdrawal syndrome: decrease of prostate specific antigen and clinical response to estramustine phosphate withdrawal Presse Medicale 26(13): 611
Martina, B.; Lorz, W.; Frach, B.; Bart, T.; Battegay, E.J. 1999: The effects of mibefradil and enalapril on 24-hour blood pressure control and left ventricular mass in patients with mild to moderate hypertension: double-blind, randomized trial Journal of Cardiovascular Pharmacology 33(4): 647-651
Ortayli, N.; Bulut, A.şe.; Ozugurlu, M.; Cokar, M. 2005: Why withdrawal? Why not withdrawal? Men's perspectives Reproductive Health Matters 13(25): 164-173
Jantz, L.L. 1977: Withdrawal, healing, and prevention of recurrence. Methods, possibilities and prognosis of withdrawal, healing, and recurrence prevention in alcoholics Zfa. Zeitschrift für Allgemeinmedizin 53(26): 1538-1543
2009: Desvenlafaxine: application withdrawal. Desvenlafaxine: withdrawal of marketing application for depression also Prescrire International 18(103): 197
Parent, M.; Jadot, M.; Toussaint, C.; Masson, A.M. 1982: Alcohol withdrawal Revue Medicale de Liege 37(18): 618-622
Mareth, T.R.; Brown, T.M. 1996: SSRI withdrawal Journal of Clinical Psychiatry 57(7): 310
Banas, R.; Müller, C.A.; Volkmar, K.; Heinz, A. 2011: Alcohol withdrawal MMW Fortschritte der Medizin 153(14): 70-72
Keks, N.A.; Burrows, G.D. 1994: Withdrawal of remoxipride Medical Journal of Australia 160(9): 591
Colquhoun, J.P. 1991: Withdrawal wobblies Australian Family Physician 20(6): 844-845
Rutter, J.M. 1991: Withdrawal of Alugan Veterinary Record 128(17): 410
Pedersen, R.; Førde, R. 2008: Treatment withdrawal Tidsskrift for den Norske Laegeforening: Tidsskrift for Praktisk Medicin Ny Raekke 128(4): 477; Author Reply 477-8
Morin, R. 1983: The withdrawal of services Nursing Quebec 3(2): 17-19
Chiang, W.K.; Goldfrank, L.R. 1990: Substance withdrawal Emergency Medicine Clinics of North America 8(3): 613-631
André, A.; Lejeune, G.; Bouillenne, C.; Rigo, G.; Brocteur, J.; de Rudder, Y. 1977: Withdrawal and transplantation of organs Revue Medicale de Liege 32(9): 265-273
Berlin, C.S. 1996: Fluoxetine withdrawal symptoms Journal of Clinical Psychiatry 57(2): 93-94